Научная литература
booksshare.net -> Добавить материал -> Медицина -> Насонов Е.Л. -> "Антифосфолипидный синдром" -> 154

Антифосфолипидный синдром - Насонов Е.Л.

Насонов Е.Л. Антифосфолипидный синдром — М.: Литтерра, 2004. — 440 c.
ISBN 5-98216-010-5
Скачать (прямая ссылка): antisindrom2004.pdf
Предыдущая << 1 .. 148 149 150 151 152 153 < 154 > 155 156 157 158 159 160 .. 184 >> Следующая

60. Hankey GJ. Warfarin-aspirin recurrent stroke study (WARSS) trial. Is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke? Stroke 2002; 33: 1723—1726.
61. Adam HP. Emergent use of anticoagulan-tion for treatment of patients with ischemic stroke. Stroke 2002; 33: 856—861.
62. Sandercock P, Gubitz G, Foley P, Counsell C. Antiplatelet therapy for acute ischemic stroke. Cochrane Database Syst Rev 2003; CD000029.
63. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fubrilation: a meta analysis. Ann Intern Med 1999; 131: 492—501.
64. Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. New Engl J Med 2001; 345: 1444—1451.
65. Alberts MJ. Update on the treatment and prevention of ischemic stroke. Curr Med Research and Opinions 2003; 19: 438—441.
66. Ruiz-Irastorz.a G, Khamashta M, Hunt B, et al. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome. Analysis of a series of 66 patients with oral anticoagulation to a target international normalization ratio of 3.5. Arch Untern Med 2002; 162: 1164—1169.
67. Castellino G, Cuadrado MJ, Godfrey T, et al. Characteristics of patients with antiphospho-lipid syndrome with major bleeding after oral anticoagulant treatment Ann Rheum Dis 2001; 60: 527—530.
68. WARSS, APASS, PICSS and HAS study groups. The feasibility of a collaborative, doubleblind study using anticoagulant: the warfarin-aspirin recurrent stroke study (WARSS), the antiphospholipid antibody in stroke stusy (APASS), the patients foramen ovale study (PICSS) and the hemostatic system study (HAS). Cerebrovascular Dis 1997; 7: 100—112.
69. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127: 177.
70. Robert A, Le Querrec A, Delahousse B, et al. Control of oral anticoagulation in patients with the antiphospholipid syndrome — Influence of the lupus anticoagulant on international normalized ratio. Thromb Haemost 1998; 80: 99.
71. Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome. Br J Haematol 1997; 98: 887.
72. Douketis JD, Crowther MA, Julian JA, et al. The effects of low-intensity warfarin on coagulation activation in patients with antiphospholipid antibodies and systemic lupus erythematosus. Thromb Haemost 1999; 82:1028.
73. Tripodi A, Chantarangkul V, Clerici M, et al. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol 2001; 115: 672.
74. Решетняк ТМ, Широкова ИЕ, Кондратьева ДВЮ и соавт. Варфарин в комплекс-
SHS-OOO4.qxd 21.11.2006 16:56 Page
ГЛАВА 13. Антифосфолипидный синдром: профилактика, лечение и прогноз
ной терапии антифосфолипидного синдрома: предварительные результаты. Научно-практическая ревматология, 2003; 3: 37—41.
75. Crowther MA, Julian J, McCarty D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomized controlled trial. Lancet 2000; 356: 144—1553.
76. Nee R, Doppenschmidt D, Donovan DJ, Andrews TC. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagu-lation. Am J Cardiol 1999; 83: 286—8, A6-A7.
77. Markis M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction og the coagulopathy. Thromb Haemost 1997; 77: 477—480.
78. Chapman J, Randl JH, Levine SR, et al. Non-stroke neurological syndrome associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 2003; 12: 514—517.
79. Cuadrado MJ, Sanna G, Sharief M, et al. Double blind, crossover, randomized trial comparing low molecular weight heparin versus placebo in the treatment of chronic headache in patients with antiphospholipid syndrome. ACR/ARHP Annual Scientific Meeting October 24—28, 2003; Orlando, 883 (abst).
80. Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 2003; 12: 518—523.
81. Espinola-Zavaleta N, Vargas-Barron J, Colmenares-Galvis T, et al. Echocardiographic evaluation of patients with primary antiphospho-lipid syndrome. Am Heart J 1999; 137: 973—978.
82. Berkum Y, Elami A, Meir K, et al. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. ACR/ARHP Annual Scientific Meeting October 24—28, 2003; 877 (abst).
83. Weitz JI. Low-molecular-weight heparins. New Engl JMed 1997; 337: 688—698.
84. Moonis M, Fisher M. Considering the role of heparin and low-molecular-weight heparins in acute ishchemic stroke. Stroke 2003; 33: 1927— 1933.
Предыдущая << 1 .. 148 149 150 151 152 153 < 154 > 155 156 157 158 159 160 .. 184 >> Следующая

Реклама

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed

Есть, чем поделиться? Отправьте
материал
нам
Авторские права © 2009 BooksShare.
Все права защищены.
Rambler's Top100

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed